Telix lands on fast track

Posted 18 April 2024 PM

Melbourne radiopharmaceutical company Telix has landed a Fast Track designation from the FDA, as it progresses what is likely to be its third commercial product.

The designation was awarded to LX101-CDx, branded Pixclara, for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). There is no FDA-approved targeted PET agent for brain cancer imaging in the US, although it's currently included in both the US and European guidelines for the imaging of gliomas.

To see the whole article, please login